Obesity has direct consequences on health and is associated with the
onset of aggressive cancers, but the mechanisms underlying this phenomenon are little known.
More precise dosing methods and cellular engineering techniques show promise in the effort to improve
treatment of aggressive cancers with personalized cellular therapies, according to new studies from researchers in the Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania and The Children's Hospital of Philadelphia.
«The goal is to find specific
biomarkers of aggressive cancers,» said Charles Brendler, MD, Co-Director of the John and Carol Walter Center for Urological Health & Program for Personalized Cancer Care at NorthShore and author of the study.
In the largest group of results to date, researchers from Penn Medicine's Abramson Cancer Center and other institutions have shown in clinical trials that the malaria drug hydroxychloroquine (HCQ) blocked autophagy in a
host of aggressive cancers — glioblastoma, melanoma, lymphoma and myeloma, renal and colon cancers — and in some cases helped stabilize disease.
«Pinpointing specific differences in how cancer cells function is critical in the development of targeted treatments, especially for these
types of aggressive cancers that often recur and don't respond well to standard treatments like chemotherapy.»
Combined treatment with two cancer immunotherapy drugs — one a novel immune modulator and one that focuses and activates the antitumor immune response — significantly prolonged survival in mouse
models of the aggressive cancer malignant mesothelioma.
According to recent Bulletproof Radio (iTunes) podcast guest Kris Smith, MD, a top neurosurgeon who specializes in brain tumors at the Barrow Neurological Institute in Phoenix, the
downside of some aggressive cancer treatments is that they can cause lifelong side effects in survivors.
The first expedition returned with reports of a pristine, Edenic landscape; all the members of the second expedition committed suicide; the third expedition died in a hail of gunfire as its members turned on one another; the members of the eleventh expedition returned as shadows of their former selves, and within months of their return, all had
died of aggressive cancer.
«These observations in mouse models of prostate cancer, using a sophisticated genetic approach developed by James Horner at MD Anderson, illuminate a clinical path hypothesis for combining immune checkpoint blockades with MDSC - targeted therapies in the treatment
of this aggressive cancer.»